IP Library › Granted Patent US 12,441,814
Granted Patent B2
US 12,441,814 · App. 17/272,136 · Granted Oct 14, 2025

Compositions and methods for enhancing donor oligonucleotide-based gene editing

Inventors: Elias Quijano (Durham, CT); Audrey Turchick (Chelmsford, MA); Peter Glazer (Guilford, CT)
Assignee: YALE UNIVERSITY
C07K16/44A61K31/7088A61K35/14A61K47/6937A61K48/0008A61P43/00C12N15/102C12N15/11A61K2039/505C07K16/40C07K2317/622C07K2317/626C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,441,814
App. No.
17/272,136
Granted
Oct 14, 2025
Kind
B2
Abstract

Compositions for enhanced gene editing and methods of use thereof are. The composition contains a cell-penetrating antibody and a donor oligonucleotide containing a sequence that can correct a mutation in a cell's genome. Preferably, the composition does not contain a nuclease, PNA, or nanoparticle. The compositions are used to modify the genome of a cell by contacting the cell with an effective amount of the composition. Genomic modification occurs at a higher frequency both ex vivo and in vivo, when cells are contacted with the cell-penetrating antibody and donor oligonucleotide as compared to the absence of the cell-penetrating antibody.

Claims (29)

1. A method of modifying the genome of a cell comprising contacting the cell with an effective amount of a composition comprising a non-covalent complex comprising:

(i) a donor oligonucleotide comprising a sequence that can correct at least one mutation in the cell's genome; and

(ii) an antibody or an antigen-binding fragment thereof,

wherein the antibody or antigen-binding fragment thereof comprises:

(a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 16,

(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17,

(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 18,

(d) a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 24,

(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25, and

(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26;

and wherein the composition does not comprise a nuclease, a triplex-forming peptide nucleic acid oligomer, or nanoparticles.

2. The method of claim 1 , wherein the method is conducted in vivo in a subject.

3. The method of claim 1 , wherein the method is conducted ex vivo.

4. The method of claim 1 , wherein the cell is a hematopoietic stem cell.

5. The method of claim 1 , wherein the donor oligonucleotide comprises single stranded or double stranded DNA.

6. The method of claim 1 , wherein the donor oligonucleotide comprises one or more inserted, substituted, or deleted nucleotides relative to a target gene in the cell's genome.

7. A method to treat a disease or disorder comprising administering a therapeutically effective amount of a modified cell obtained according to the method of claim 1 to a subject in need thereof.

8. The method of claim 7 , wherein the disease or disorder is selected from the group consisting of hemophilia, muscular dystrophy, globinopathies, cystic fibrosis, xeroderma pigmentosum, lysosomal storage diseases, immune deficiency syndromes, tyrosinemia, Fanconi anemia, spherocytosis, alpha-1-anti-trypsin deficiency, Wilson's disease, Leber's hereditary optic neuropathy, and chronic granulomatous disorder.

9. The method of claim 8 , wherein the immune deficiency syndromes is X-linked severe combined immunodeficiency or ADA deficiency.

10. The method of claim 1 , wherein the at least one mutation is in a gene encoding coagulation factor VIII, a gene encoding coagulation factor IX, a gene encoding dystrophin, a gene encoding beta-globin, a CFTR gene, an XPC gene, an XPD gene, a gene encoding DNA polymerase eta, a FANCA gene, a FANCB gene, a FANCC gene, a FANCD1 gene, a FANCD2 gene, a FANCE gene, a FANCF gene, a FANCG gene, a FANCI gene, a FANCJ gene, a FANCL gene, a SPTA1 gene or other spectrin genes, an ANK1 gene, a SERPINA1 gene, an ATP7B gene, an IL2RG gene, an ADA gene, an FAH gene, a CYBA gene, a CYBB gene, an NCF1 gene, an NCF2 gene, or an NCF4 gene.

11. The method of claim 1 , wherein the cell's genome has a mutation underlying a disease or disorder selected from the group consisting of hemophilia, muscular dystrophy, globinopathies, cystic fibrosis, xeroderma pigmentosum, lysosomal storage diseases, immune deficiency syndromes, tyrosinemia, Fanconi anemia, spherocytosis, alpha-1-anti-trypsin deficiency, Wilson's disease, Leber's hereditary optic neuropathy, and chronic granulomatous disorder.

12. The method of claim 11 , wherein the immune deficiency syndromes is X-linked severe combined immunodeficiency or ADA deficiency.

13. The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a monovalent, divalent, or multivalent single chain variable fragment (scFv) or a diabody.

14. The method of claim 1 , wherein the donor oligonucleotide is single stranded or double stranded RNA.

15. The method of claim 1 , wherein the oligonucleotide sequence corresponds to a portion of the wild-type sequence of the gene.

16. The method of claim 1 , wherein the method does not comprise contacting the cell with a PNA.

17. The method of claim 1 , wherein the donor oligonucleotide is single stranded DNA.

18. The method of claim 1 , wherein the donor oligonucleotide comprises a modification to a nucleobase, a sugar moiety, or a linkage.

19. The method of claim 1 , wherein the method is conducted in vitro.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2021
From: QUIJANO, ELIAS; TURCHICK, AUDREY; GLAZER, PETER
To: YALE UNIVERSITY
Reel/Frame 055982/0418 →
Continuity (2)
Provisional Application 62725920 · Aug 31, 2018
Related Publication 20210340280A1 · Nov 4, 2021
References Cited (278)
US 4714680A · Civin · 1987 [cited by applicant]
US 4812397A · Weisbart · 1989 [cited by applicant]
US 4965204A · Civin · 1990 [cited by applicant]
US 5034506A · Summerton et al. · 1991 [cited by applicant]
US 5061620A · Tsukamoto et al. · 1991 [cited by applicant]
US 5075109A · Tice et al. · 1991 [cited by applicant]
US 5356802A · Chandrasegaran · 1994 [cited by applicant]
US 5422251A · Fresco · 1995 [cited by applicant]
US 5436150A · Chandrasegaran · 1995 [cited by applicant]
US 5487994A · Chandrasegaran · 1996 [cited by applicant]
US 5527675A · Coull et al. · 1996 [cited by applicant]
US 5539082A · Nielsen et al. · 1996 [cited by applicant]
US 5623049A · Löbberding et al. · 1997 [cited by applicant]
US 5643741A · Tsukamoto et al. · 1997 [cited by applicant]
US 5677136A · Simmons et al. · 1997 [cited by applicant]
US 5714331A · Buchardt et al. · 1998 [cited by applicant]
US 5716827A · Tsukamoto et al. · 1998 [cited by applicant]
US 5736336A · Buchardt et al. · 1998 [cited by applicant]
US 5750397A · Tsukamoto et al. · 1998 [cited by applicant]
US 5759793A · Schwartz et al. · 1998 [cited by applicant]
US 5773571A · Nielsen et al. · 1998 [cited by applicant]
US 5786571A · Bethel et al. · 1998 [cited by applicant]
US 5945337A · Brown · 1999 [cited by applicant]
US 5962426A · Glazer · 1999 [cited by applicant]
US 6140081A · Barbas · 2000 [cited by applicant]
US 6261841B1 · Cohen et al. · 2001 [cited by applicant]
US 6303376B1 · Glazer · 2001 [cited by applicant]
US 6326479B1 · Gildea et al. · 2001 [cited by applicant]
US 6441130B1 · Egholm et al. · 2002 [cited by applicant]
US 6453242B1 · Eisenberg et al. · 2002 [cited by applicant]
US 6534261B1 · Cox, III et al. · 2003 [cited by applicant]
US 6610512B1 · Barbas · 2003 [cited by applicant]
US 6746838B1 · Choo et al. · 2004 [cited by applicant]
US 6866997B1 · Choo et al. · 2005 [cited by applicant]
US 6919208B2 · Levy et al. · 2005 [cited by applicant]
US 7067617B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7078389B2 · Glazer et al. · 2006 [cited by applicant]
US 7189396B1 · Weisbart · 2007 [cited by applicant]
US 7279463B2 · Glazer · 2007 [cited by applicant]
US 8309356B2 · Glazer · 2012 [cited by applicant]
US 8658608B2 · Glazer et al. · 2014 [cited by applicant]
US 9193758B2 · Ly et al. · 2015 [cited by applicant]
US RE46211E · Weisbart · 2016 [cited by applicant]
US 11136597B2 · Saltzman · 2021 [cited by examiner]
US 11590242B2 · Zhou et al. · 2023 [cited by applicant]
US 11850284B2 · Quijano et al. · 2023 [cited by applicant]
US 11872286B2 · Quijano et al. · 2024 [cited by applicant]
US 20020165356A1 · Barbas, III et al. · 2002 [cited by applicant]
US 20030148352A1 · Glazer · 2003 [cited by applicant]
US 20040197892A1 · Moore et al. · 2004 [cited by applicant]
US 20070154989A1 · Barbas, III · 2007 [cited by applicant]
US 20070213269A1 · Barbas, III et al. · 2007 [cited by applicant]
US 20100172882A1 · Glazer et al. · 2010 [cited by applicant]
US 20110145940A1 · Voytas et al. · 2011 [cited by applicant]
US 20110262406A1 · Del Campo et al. · 2011 [cited by applicant]
US 20110268810A1 · Saltzman et al. · 2011 [cited by applicant]
US 20110293585A1 · Del Campo et al. · 2011 [cited by applicant]
US 20140342003A1 · Saltzman et al. · 2014 [cited by applicant]
US 20150290244A1 · June et al. · 2015 [cited by applicant]
US 20150376279A1 · Hansen et al. · 2015 [cited by applicant]
US 20160237165A1 · Weisbart et al. · 2016 [cited by applicant]
US 20170281795A1 · Geall et al. · 2017 [cited by applicant]
US 20170283830A1 · Saltzman et al. · 2017 [cited by applicant]
US 20180127509A1 · Armstrong · 2018 [cited by applicant]
US 20210338815A1 · Quijano et al. · 2021 [cited by applicant]
US 20230032060A1 · Quijano et al. · 2023 [cited by applicant]
US 20230085308A1 · Quijano et al. · 2023 [cited by applicant]
US 20230093460A1 · Quijano et al. · 2023 [cited by applicant]
US 20230093888A1 · Quijano et al. · 2023 [cited by applicant]
US 20230227583A1 · Quijano et al. · 2023 [cited by applicant]
US 20230272115A1 · Quijano et al. · 2023 [cited by applicant]
US 20230277658A1 · Quijano et al. · 2023 [cited by applicant]
US 20240285774A1 · Quijano et al. · 2024 [cited by applicant]
US 20240285775A1 · Quijano et al. · 2024 [cited by applicant]
JP 2010527618A · 2010 [cited by applicant]
JP 2017509328A · 2017 [cited by applicant]
WO WO9501364A1 · 1995 [cited by applicant]
WO WO9639195A2 · 1996 [cited by applicant]
WO WO9640271A1 · 1996 [cited by applicant]
WO WO9640898A1 · 1996 [cited by applicant]
WO WO1997032602A1 · 1997 [cited by applicant]
WO WO9853059A1 · 1998 [cited by applicant]
WO WO03016496A2 · 2003 [cited by applicant]
WO WO03052071A2 · 2003 [cited by applicant]
WO WO2008086529A2 · 2008 [cited by applicant]
WO WO2008091911A2 · 2008 [cited by applicant]
WO WO2008148063A1 · 2008 [cited by applicant]
WO WO2010123983A1 · 2010 [cited by applicant]
WO WO2011053989A2 · 2011 [cited by applicant]
WO WO2011072246A2 · 2011 [cited by applicant]
WO WO2011133802A1 · 2011 [cited by applicant]
WO WO2011133803A1 · 2011 [cited by applicant]
WO WO2012135831A1 · 2012 [cited by applicant]
WO WO2013082529A1 · 2013 [cited by applicant]
WO WO2013138662A1 · 2013 [cited by applicant]
WO WO2013176772A1 · 2013 [cited by applicant]
WO WO2014018423A2 · 2014 [cited by applicant]
WO WO2015106290A1 · 2015 [cited by applicant]
WO WO2015134607A1 · 2015 [cited by applicant]
WO WO2015143177A1 · 2015 [cited by applicant]
WO WO2016033321A1 · 2016 [cited by applicant]
WO WO2016033324A1 · 2016 [cited by applicant]
WO WO2016081621A1 · 2016 [cited by applicant]
WO WO2017015101A1 · 2017 [cited by applicant]
WO WO2017109177A1 · 2017 [cited by applicant]
WO WO2017143042A2 · 2017 [cited by applicant]
WO WO2017143061A1 · 2017 [cited by applicant]
WO WO2017218825A1 · 2017 [cited by applicant]
WO WO2018187493A1 · 2018 [cited by applicant]
WO WO2019018428A1 · 2019 [cited by applicant]
WO WO2019152806A1 · 2019 [cited by applicant]
WO WO2020047344A1 · 2020 [cited by applicant]
WO WO2020047353A1 · 2020 [cited by applicant]
WO WO2021042060A1 · 2021 [cited by applicant]
Makadia and Siegel. (2011) “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.” Polymers (Basel) 3(3): 1377-1397. (Year: 2011). [cited by examiner]
Quijano et al. U.S. Appl No. 17/272,151. Compositions and Methods for Enhancing Triplex and Nuclease-Based Gene Editing (Year: 2021). [cited by examiner]
Quijano et al. U.S. Appl. No. 18/054,080. Compositions and Methods for Enhancing Donor Oligonucleotide-Based Gene Editing. (Year: 2022). [cited by examiner]
Quijano et al. U.S. Appl No. 18/054,101. Compositions and Methods for Enhancing Triplex and Nuclease-Based Gene Editing. (Year: 2022). [cited by examiner]
U.S. Appl No. 17/272,151. Compositions and Methods for Enhancing Triplex and Nuclease-Based Gene Editing. Published 2021 in US 20210338815 A1. (Year: 2021). [cited by examiner]
Weisbart (Scientific Reports (2015) 5: 12002) (Year: 2015). [cited by examiner]
Attwood, T.K., “Genomics. The Babel of Bioinformatics,” Science 290(5491):471-473, American Association for the Advancement of Science, United States (Oct. 2000). [cited by applicant]
Non-Final Office Action mailed Oct. 12, 2023, in U.S. Appl. No. 18/054,080, Quijano, E., et al., filed Nov. 9, 2022, 11 pages. [cited by applicant]
Final Office Action mailed Mar. 27, 2024, in U.S. Appl. No. 18/054,080, Quijano, E., et al., filed Nov. 9, 2022, 13 pages. [cited by applicant]
Non-Final Office Action mailed Sep. 13, 2023, in U.S. Appl. No. 18/054,101, Quijano, E., et al., filed Nov. 9, 2022, 17 pages. [cited by applicant]
Final Office Action mailed Mar. 18, 2024, in U.S. Appl. No. 18/054,101, Quijano, E., et al., filed Nov. 9, 2022, 13 pages. [cited by applicant]
Piche-Nicholas, N. M., et al., “Changes in Complementarity-determining Regions Significantly Alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics,” MABS 10(1):81-94, Taylor & Francis, United States … [cited by applicant]
Skolnick, J, and Fetrow, U.S., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic era,” Trends in Biotechnology 18:34-39, Elsevier Science Publishers, United Kin… [cited by applicant]
Aguado, M. T., and Lambert, P. H., “Controlled-release vaccines—biodegradable polylactide/polyglycolide (PL/PG) microspheres as antigen vehicles,” Immunobiology 184(2-3):113-125, Elsevier, Netherlands (Feb. 1992). [cited by applicant]
Aiuti, A., et al., “Gene therapy for immunodeficiency due to adenosine deaminase deficiency,” N Engl J Med 360(5):447-458, Massachusetts Medical Society, United States (Jan. 2009). [cited by applicant]
Akinc, A., et al., “Synthesis of poly(beta-amino ester)s optimized for highly effective gene delivery,” Bioconjug Chem 14(5):979-988, American Chemical Society, United States (Sep.-Oct. 2003). [cited by applicant]
Alton, E. W. F. W., et al., “Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial,” Lancet Respir Med 3(9):684-691, Elsevi… [cited by applicant]
Alton, E. W. F. W., et al., “A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis,” Thorax 68(11):1075-1077, BioMed Central Ltd… [cited by applicant]
Armstrong, D. K., et al., “Gene therapy in cystic fibrosis,” Arch Dis Child 99(5):465-468, BioMed Central Ltd., United Kingdom (May 2014). [cited by applicant]
Bahal, R., et al., “In vivo correction of anaemia in β-thalassemic mice by γPNA-mediated gene editing with nanoparticle delivery,” Nat Commun 7:13304, Nature Publishing Group, United Kingdom (Oct. 2016). [cited by applicant]
Bentin, T., et al., “Combined triplex/duplex invasion of double-stranded DNA by “tail-clamp” peptide nucleic acid,” Biochemistry 42(47):13987-13995, American Chemical Society, United States (Dec. 2003). [cited by applicant]
Bentin, T., et al., “Structural diversity of target-specific homopyrimidine peptide nucleic acid-dsDNA complexes,” Nucleic Acids Res 34(20):5790-5799, Oxford University Press, United Kingdom (Oct. 2006). [cited by applicant]
Beutler, E., and Grabowski, G. A., “Gaucher Disease,” in [cited by applicant]
Braasch, D. A., and Corey, D. R., “Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA,” Chem Biol 8(1):1-7, Cell Press, United States (Jan. 2001). [cited by applicant]
Bramwell, V. W., et al., “Particulate delivery systems for biodefense subunit vaccines,” Adv Drug Deliv Rev 57(9):1247-1265, Elsevier, Netherlands (Jun. 2005). [cited by applicant]
Cartier, N., et al., “Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy,” Science 326(5954):818-823, American Association for the Advancement of Science, United States (Nov. … [cited by applicant]
Cejka, P., et al., “DNA end resection by Dna2-Sgs1-RPA and its stimulation by Top3-Rmil and Mre11-Rad50-Xrs2,” Nature 467(7311):112-116, Nature Publishing Group, United Kingdom (Sep. 2010). [cited by applicant]
Cermak, T., et al., “Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting,” Nucleic Acids Res 39(12):e82, 11 pages, Oxford University Press, United Kingdom (Jul. 2011). [cited by applicant]
Chin, J. Y., et al., “Correction of a splice-site mutation in the beta-globin gene stimulated by triplex-forming peptide nucleic acids,” Proc Natl Acad Sci USA 105(36):13514-13519, National Academy of Sciences, United S… [cited by applicant]
Chothia, C., and Lesk, A. M., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol 196(4):901-917, Elsevier Science, United States (Aug. 1987). [cited by applicant]
Chu, V. T., et al., “Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells, ” Nat Biotechnol 33(5):543-548, Nature Publishing Group, United Kingdom (Mar. 2… [cited by applicant]
Cong, L., “Multiplex genome engineering using CRISPR/Cas systems,” Science 339(6121):819-823, American Association for the Advancement of Science, United States (Feb. 2013). [cited by applicant]
Cradick, T. J., et al., “CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity,” Nucleic Acids Res 41(20):9584-9592, Oxford University Press, United Kingdom (Nov. 2013). [cited by applicant]
Cruz, L. J., et al., “Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro,” J Control Release 144(2):118-126, Elsevier, Netherlands (Jun. 2010). [cited by applicant]
Cu, Y., et al., “In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery,” J Control Release 156(2):258-264, Elsevier, Netherlands (Dec. 2011). [cited by applicant]
Davis, P. B., “Cystic fibrosis since 1938,” Am J Respir Crit Care Med 173(5):475-482, American Thoracic Society, United States (Mar. 2006). [cited by applicant]
Davis, P. B., “Cystic fibrosis,” Pediatr Rev 22(8):257-264, American Academy of Pediatrics, United States (Aug. 2001). [cited by applicant]
Desai, M. P., et al., “The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent,” Pharm Res 14(11):1568-1573, Springer Science+Business Media, Germany (Nov. 1997). [cited by applicant]
El Dib, R. P., and Pastores, G. M., “Laronidase for treating mucopolysaccharidosis type I,” Genet Mol Res 6(3):667-674, FUNEPC-RP, Brazil (Sep. 2007). [cited by applicant]
Doudna, J. A., and Charpentier, E., “The new frontier of genome engineering with CRISPR-Cas9,” Science 346(6213):1258096, American Association for the Advancement of Science, United States (Nov. 2014). [cited by applicant]
Endoh, T., and Ohtsuki, T., “Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape,” Adv Drug Deliv Rev 61(9):704-709, Elsevier, Netherlands (Jul. 2009). [cited by applicant]
Fields, R. J., et al., “Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung,” Adv Healthc Mater 4(3):361-366, John Wiley and Sons Ltd., United Kingdom (Feb. 201… [cited by applicant]
Genbank, “immunoglobulin heavy chain, partial [Mus musculus],” ncbi.nlm.nih.gov, Accession No. AAA65679.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/protein/AAA65679] on Jan. 14, 2022, 1 page. [cited by applicant]
Genbank, “immunoglobulin light chain, partial [Mus musculus],” ncbi.nlm.nih.gov, Accession No. AAA65681.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/protein/AAA65681] on Jan. 14, 2022, 1 page. [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “Mouse Ig rearranged L-chain gene, partial cds,” ncbi.nlm.nih.gov, Accession No. L16981.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/nuccore/L16981] on Jan. 14, 2022, 1 page. [cited by applicant]
Genbank, “Mouse Ig rearranged H-chain gene, partial cds,” ncbi.nlm.nih.gov, Accession No. L16982.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/nuccore/L16982] on Jan. 14, 2022, 1 page. [cited by applicant]
Genbank, “Mouse Ig rearranged kappa-chain mRNA V-region,” ncbi.nlm.nih.gov, Accession No. L34051.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/nuccore/L34051] on Jan. 14, 2022, 1 page. [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “ [cited by applicant]
Genbank, “Human beta globin region on chromosome 11,” ncbi.nlm.nih.gov, Accession No. U01317.1, accessed at URL:[https://www.ncbi.nlm.nih.gov/nuccore/U01317] on Jan. 14, 2022, 35 pages. [cited by applicant]
Goncz, K. K., et al., “Small fragment homologous replacement-mediated modification of genomic beta-globin sequences in human hematopoietic stem/progenitor cells,” Oligonucleotides 16(3):213-224, Mary Ann Liebert Inc., U… [cited by applicant]
Händel, E-M., and Cathomen, T., “Zinc-finger nuclease based genome surgery: it's all about specificity,” Curr Gene Therapy 11(1):28-37, Bentham Science Publishers, United Arab Emirates (Feb. 2011). [cited by applicant]
Hanna, J., et al., “Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin,” Science 318(5858):1920-1923, American Association for the Advancement of Science, United States (Dec. 2007). [cited by applicant]
Hansen, M. E., et al., “High-affinity triplex targeting of double stranded DNA using chemically modified peptide nucleic acid oligomers,” Nucleic Acids Res 37(13):4498-4507, Oxford University Press, United Kingdom (Jul.… [cited by applicant]
He, W., et al., “The structure of a gamma-modified peptide nucleic acid duplex,” Mol BioSyst 6(9):1619-1629, Royal Society of Chemistry, United Kingdom (Sep. 2010). [cited by applicant]
Helleday, T., et al., “DNA double-strand break repair: from mechanistic understanding to cancer treatment,” DNA Repair (Amst) 6(7):923-935, Elsevier, Netherlands (Jul. 2007). [cited by applicant]
Herrmann, A., et al., “An effective cell-penetrating antibody delivery platform,” JCI Insight 4(14):e127474, American Society for Clinical Investigation, United States (Jul. 2019). [cited by applicant]
Holt, N., et al., “Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo,” Nat Biotechnol 28(8):839-847, Nature Publishing Group, United Kingdom (Aug. 2010). [cited by applicant]
Huang, H., et al., “Preparation and determination of optical purity of γ-lysine modified peptide nucleic acid analogues,” Arch Pharm Res 35(3):517-522, Springer Science+Business Media, Germany (Mar. 2012). [cited by applicant]
Huang, A., et al., “Functional silencing of hepatic microsomal glucose-6-phosphatase gene expression in vivo by adenovirus-mediated delivery of short hairpin Rna,” FEBS Lett 558(1-3):69-73, Wiley on behalf of FEBS, Unit… [cited by applicant]
Huang, L. C., et al., “Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest,” Proc Natl Acad Sci USA 93(10):4827-4832, National Academy of Sciences, United States (May … [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048953, European Patent Office, Netherlands, mailed on Nov. 19, 2019, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048962, European Patent Office, Netherlands, mailed on Nov. 20, 2019, 11 pages. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/048823, European Patent Office, Netherlands, mailed on Oct. 19, 2020, 14 pages. [cited by applicant]
Jain, D. R., et al., “Influence of pendant chiral C(γ)-(alkylideneamino/guanidino) cationic side- chains of PNA backbone on hybridization with complementary DNA/RNA and cell permeability,” J Org Chem 79(20):9567-9577, A… [cited by applicant]
Jekimovs, C., et al., “Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising,” Front Oncol 4:86, Frontiers Media S.A., Switzerland (Apr. 2014). [cited by applicant]
Jiang, W., et al., “Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens,” Adv Drug Deliv Rev 57(3):391-410, Elsevier, Netherlands (Jan. 2005). [cited by applicant]
Jinek, M., et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science 337(6096):816-821, American Association for the Advancement of Science, United States (Aug. 2012). [cited by applicant]
Kabat, E.A. et al., “Sequences of proteins of immunological interest,” U.S. Dept. of Health and Human Services, United States (1991). [cited by applicant]
Kaihatsu, K., et al., “Extending recognition by peptide nucleic acids (PNAs): binding to duplex DNA and inhibition of transcription by tail-clamp PNA-peptide conjugates,” Biochemistry 42(47):13996-14003, American Chemic… [cited by applicant]
Karen, J. K., et al., “Angiokeratoma corporis diffusum (Fabry disease),” Dermatol Online J 11(4):8, University of California, Davis, United States (Dec. 2005). [cited by applicant]
Kim, Y-G., et al., “Insertion and deletion mutants of FokI restriction endonuclease,” J Biol Chem 269(50):31978-31982, Elsevier, Netherlands (Dec. 1994). [cited by applicant]
Kim, Y-G., and Chandrasegaran, S., “Chimeric restriction endonuclease,” Proc Natl Acad Sci USA 91(3):883-887, National Academy of Sciences, United States (Feb. 1994). [cited by applicant]
Konstan, M. W., et al., “Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution,” Hum… [cited by applicant]
Koppelhus, U., and Nielsen, P. E., “Cellular delivery of peptide nucleic acid (PNA),” Adv Drug Deliv Rev 55(2):267-280, Elsevier, Netherlands (Feb. 2003). [cited by applicant]
Kowalczykowski, S. C., “Snapshots of DNA repair,” Nature 453(7194):463-466, Nature Publishing Group, United Kingdom (May 2008). [cited by applicant]
Krogh, B. O., and Symington, L. S., “Recombination proteins in yeast,” Annu Rev Genet 38:233-271, Annual Reviews, United States (Dec. 2004). [cited by applicant]
Kuhn, H., et al., “Sequence specificity at targeting double-stranded DNA with a γ-PNA oligomer modified with guanidinium G-clamp nucleobases,” Artif DNA PNA XNA 1(1):45-53, Taylor & Francis, United States (Jul. 2010). [cited by applicant]
Li, L., et al., “Functional domains in Fok I restriction endonuclease,” Proc Natl Acad Sci USA 89(10):4275-4279, National Academy of Sciences, United States (May 1992). [cited by applicant]
Li, L., and Chandrasegaran, S., “Alteration of the cleavage distance of Fok I restriction endonuclease by insertion mutagenesis,” Proc Natl Acad Sci USA 90(7):2764-2768, National Academy of Sciences, United States (Apr.… [cited by applicant]
Lorenz, C., et al., “Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells,” Bioorg Med Chem Lett 14(19):4975-4977, Elsevier, Netherlands (Oct. 2004). [cited by applicant]
Luens, K. M., et al., “Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin-cells with preserved ability to engraft SCID-hu … [cited by applicant]
Ma, M. Y., et al., “Nuclease-resistant external guide sequence-induced cleavage of target RNA by human ribonuclease P,” Antisense Nucleic Acid Drug Dev 8(5):415-426, Mary Ann Liebert, Inc., United States (Oct. 1998). [cited by applicant]
Maeder, M. L., and Gersbach, C. A., “Genome-editing Technologies for Gene and Cell Therapy,” Mol Ther 24(3):430-446, Cell Press, United States (Mar. 2016). [cited by applicant]
Magzoub, M., et al., “N-terminal peptides from unprocessed prion proteins enter cells by micropinocytosis,” Biochem Biophys Res Commun 348(2):379-385, Elsevier, Netherlands (Sep. 2006). [cited by applicant]
Majumdar, A., et al., “Targeted gene knockout mediated by triple helix forming oligonucleotides,” Nat Genet 20(2):212-214, Nature Publishing Group, United Kingdom (Oct. 1998). [cited by applicant]
Maruyama, T., et al., “Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining,” Nat Biotechnol 33(5):538-42, Nature Publishing Group, United Kingdom (May 2015). [cited by applicant]
McNeer, N. A., et al., “Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium,” Nat Commun 6:6952, 11 pages, Nature Publishing Group, United Kingdom (Apr. 20… [cited by applicant]
McNeer, N. A., et al., “Polymer delivery systems for site-specific genome editing,” J Control Release 155(2):312-316, Elsevier, Netherlands (May 2011). [cited by applicant]
Miller, J. C., et al., “A TALE nuclease architecture for efficient genome editing,” Nat Biotechnol 29(2):143-148, Nature Publishing Group, United Kingdom (Feb. 2011). [cited by applicant]
Mimitou, E. P., and Symington, L. S., “DNA end resection: many nucleases make light work,” DNA Repair (Amst) 8(9):983-995, Elsevier, Netherlands (Sep. 2009). [cited by applicant]
Morozov, V., and Wawrousek, E. F., “Single-strand DNA-mediated targeted mutagenesis of genomic DNA in early mouse embryos is stimulated by Rad51/54 and by Ku70/86 inhibition,” Gene Ther 15(6):468-472, Nature Publishing … [cited by applicant]
Nie, H., et al., “Lysine-based peptide-functionalized PLGA foams for controlled DNA delivery,” J Control Release 138(1):64-70, Elsevier, Netherlands (Aug. 2009). [cited by applicant]
Noble, P. W., et al., “Optimizing a lupus autoantibody for targeted cancer therapy,” Cancer Res 75(11):2285-2291, American Association for Cancer Research, United States (Jun. 2015). [cited by applicant]
Nyce, J. W., and Metzger, W. J., “Dna antisense therapy for asthma in an animal model,” Nature 385(6618):721-725, Nature Publishing Group, United Kingdom (Feb. 1997). [cited by applicant]
Pâques, F., and Haber, J. E., “Multiple pathways of recombination induced by double-strand breaks in [cited by applicant]
Quijano, E., et al., “Therapeutic Peptide Nucleic Acids: Principles, Limitations, and Opportunities,” Yale J Biol Med 90(4):583-598, PubMed Central, United States (Dec. 2017). [cited by applicant]
Rapireddy, S., et al., “Strand invasion of mixed-sequence, double-helical B-DNA by γ-peptide nucleic acids containing G-clamp nucleobases under physiological conditions,” Biochemistry 50(19):3913-3918, American Chemical… [cited by applicant]
Rattray, Z., et al., “Re-engineering and evaluation of anti-DNA autoantibody 3E10 for therapeutic applications,” Biochem Biophys Res Commun 496(3):858-864, Elsevier, Netherlands (Jan. 2018). [cited by applicant]
Ricciardi, A. S., et al., “In utero nanoparticle delivery for site-specific genome editing,” Nat Commun 9(1):2481, Nature Publishing Group, United Kingdom (Jun. 2018). [cited by applicant]
Richardson, C. D., et al., “Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA,” Nat Biotechnol 34(3):339-344, Nature Publishing Group, United Kingdom … [cited by applicant]
Richardson, C. D., et al., “CRISPR-Cas9 genome editing in human cells occurs via the Fanconi anemia pathway,” Nat Genet 50(8):1132-1139, Nature Publishing Group, United Kingdom (Jul. 2018). [cited by applicant]
Riesenberg, S., and Maricic, T., “Targeting repair pathways with small molecules increases precise genome editing in pluripotent stem cells,” Nat Commun 9(1):2164, Nature Publishing Group, United Kingdom (Jun. 2018). [cited by applicant]
Rogers, F. A., et al., “Site-directed recombination via bifunctional PNA-DNA conjugates,” Proc Natl Acad Sci USA 99(26):16695-16700, National Academy of Sciences, United States (Dec. 2002). [cited by applicant]
Rump, E. T., et al., “Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein,” Biochem Pharmacol 59(11):1407-14… [cited by applicant]
Ryan, T. M., et al., “Knockout-transgenic mouse model of sickle cell disease,” Science 278(5339):873-876, American Association for the Advancement of Science, United States (Oct. 1997). [cited by applicant]
Sahu, B., et al., “Synthesis and characterization of conformationally preorganized, (R)-diethylene glycol-containing γ-peptide nucleic acids with superior hybridization properties and water solubility,” J Org Chem 76(14… [cited by applicant]
Sazani, P., et al., “Systemically delivered antisense oligomers upregulate gene expression in mouse tissues,” Nat Biotechnol 20(12):1228-1233, Nature Publishing Group, United Kingdom (Dec. 2002). [cited by applicant]
Schleifman, E. B., et al., “Targeted disruption of the CCR5 gene in human hematopoietic stem cells stimulated by peptide nucleic acids,” Chem Biol 18(9):1189-1198, Cell Press, United States (Sep. 2011). [cited by applicant]
Schwank, G., et al., “Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients,” Cell Stem Cell 13(6):653-658, Cell Press, United States (Dec. 2013). [cited by applicant]
Scott, H. S., et al., “Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications,” Hum Mutat 6(4):288-302, John Wiley & Sons, Inc., United States (1995). [cited by applicant]
Song, E., et al., “Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors,” Nat Biotechnol 23(6):709-717, Nature Publishing Group, United Kingdom (May 2005). [cited by applicant]
Soutschek, J., et al., “Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs,” Nature 432(7014):173-178, Nature Publishing Group, United Kingdom (Nov. 2004). [cited by applicant]
Staretz-Chacham, O., et al., “Lysosomal storage disorders in the newborn,” Pediatrics 123(4):1191-1207, American Academy of Pediatrics, United States (Apr. 2009). [cited by applicant]
Stirchak, E. P., et al., “Uncharged stereoregular nucleic acid analogs. 1. Synthesis of a cytosine-containing oligomer with carbamate internucleoside linkages,” J Org Chem 52(19):4202, American Chemical Society, United … [cited by applicant]
Sugiyama, T., and Kittaka, A., “Chiral peptide nucleic acids with a substituent in the N-(2-aminoethy)glycine backbone,” Molecules 18(1):287-310, Multidisciplinary Digital Publishing Institute (MDPI), Switzerland (Dec. … [cited by applicant]
Thompson, L. H., and Schild, D., “Homologous recombinational repair of DNA ensures mammalian chromosome stability,” Mutat Res 477(1-2):131-153, Elsevier, Netherlands (Jun. 2001). [cited by applicant]
Turchick, A., et al., “A cell-penetrating antibody inhibits human RAD51 via direct binding,” Nucleic Acids Res 45(20):11782-11799, Oxford University Press, United Kingdom (Nov. 2017). [cited by applicant]
Vasquez, K. M., et al., “Specific mutations induced by triplex-forming oligonucleotides in mice,” Science 290(5491):530-533, American Association for the Advancement of Science, United States (Oct. 2000). [cited by applicant]
Walkley, S. U., “Pathogenic cascades in lysosomal disease—Why so complex?,” J Inherit Metab Dis 32(2):181-189, John Wiley & Sons, Inc., United States (Apr. 2009). [cited by applicant]
Weisbart, R. H., et al., “Antibody-mediated transduction of p53 selectively kills cancer cells,” Int J Oncol 25(6):1867-1873, Spandidos Publications, Greece (Dec. 2004). [cited by applicant]
Weisbart, R. H., et al., “An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications,” J Autoimmun 11(5):539-546, Elsevier, Netherlands (Oct. 1998). [cited by applicant]
Weisbart, R. H., et al., “DNA-dependent targeting of cell nuclei by a lupus autoantibody,” Sci Rep 5:12022, Nature Publishing Group, United Kingdom (Jul. 2015). [cited by applicant]
Yamano, S., et al., “Modified Tat peptide with cationic lipids enhances gene transfection efficiency via temperature-dependent and caveolae-mediated endocytosis,” J Control Release 152(2):278-285, Elsevier, Netherlands … [cited by applicant]
Yin, H., et al., “Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype,” Nat Biotechnol 32(6):551-553, Nature Publishing Group, United Kingdom (Jun. 2014). [cited by applicant]
Yu, C., et al., “Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUCI-positive cancer cells in vitro,” PLoS One 6(9):e24077, Public Library of Science, United States (Sep. 2011). [cited by applicant]
Zack, D. J., et al., “Novel structural features of autoantibodies in murine lupus: a possible superantigen binding site?,” Immunol Cell Biol 72(6):513-520, John Wiley & Sons, Inc., United States (Dec. 1994). [cited by applicant]
Zack, D. J., et al., “DNA mimics a self-protein that may be a target for some anti-DNA antibodies in systemic lupus erythematosus,” J Immunol 154(4):1987-1994, American Association of Immunologists, United States (Feb. … [cited by applicant]
Zack, D. J., et al., “Mechanisms of cellular penetration and nuclear localization of an anti-double strand DNA autoantibody,” J Immunol 157(5):2082-2088, American Association of Immunologists, United States (Sep. 1996). [cited by applicant]
Zhou, J., et al., “Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery,” Nat Mater 11(1):82-90, Nature Publishing Group, United Kingdom (Dec. 2011). [cited by applicant]
Zielke, H. R., and Littlefield, J. W., “Repetitive synchronization of human lymphoblast cultures with excess thymidine,” Methods Cell Biol 8(0):107-121, Elsevier, Netherlands (1974). [cited by applicant]
Chen, Z., et al., “A lupus anti-DNA autoantibody mediates autocatalytic, targeted delivery of nanoparticles to tumors,” Oncotarget. 7(37):59965-59975, Impact Journals, United States (2016). [cited by applicant]
Hansen, J.E., et al., “Antibody-mediated Hsp70 protein therapy,” Brain. Res. 1088:187-196, Elsevier, Netherlands (2006). [cited by applicant]
Hansen, J.E., et al., “Antibody-Mediated p53 Protein Therapy Prevents Liver Metastasis In vivo,” Cancer Res. 67(4):1769-1774, American Association for Cancer Research, United States (2007). [cited by applicant]
Hansen, J.E., et al., “Intranuclear protein transduction through a nucleoside salvage pathway,” J. Biol. Chem. 282(29):20790-20793, American Society for Biochemistry and Molecular Biology, United States (2007). [cited by applicant]
Hansen, J.E., et al., “Targeting cancer with a lupus autoantibody,” Sci. Transl. Med. 4(157):157, American Association for the Advancement of Science, United States (2012). [cited by applicant]
Pinder, J., et al., “Nuclear domain ‘knock-in’ screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing,” Nucleic Acids Res. 43(19):9379-9392, Oxford University Press, Unit… [cited by applicant]
Spertini, F., et al., “Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis,” J. Rheumatol. 26(12):2602-2608, Journal of Rheumatol… [cited by applicant]
Turchick, A., et al., “Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells,” Oncotarget. 10(13):1272-1283, Impact Journals, United Kingdom (2019). [cited by applicant]
Weisbart, R.H., et al., “A conserved anti-DNA antibody idiotype associated with nephritis in murine and human systemic lupus erythematosus,” J. Immunol. 144(7):2653-2658, American Association of Immunologists, United St… [cited by applicant]
Weisbart, R.H., et al., “Beneficial Effects of Oral Immunoglobulin in Rheumatoid Arthritis,” J. Clin. Rheumatol. 1(2):135, Lippincott Williams &Wilkins, United States (1995). [cited by applicant]
Weisbart, R.H., et al., “Novel Protein Transfection of Primary Rat Cortical Neurons Using an Antibody That Penetrates Living Cells,” J, Immunol. 164(11):6020-6026, American Association of Immunologists, United States (2… [cited by applicant]
Weisbart, R.H., et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that minds myosin lib,” Mol. Immunol. 39(13):783-789, Pergamon Press, United Kingdom (2003). [cited by applicant]
Weisbart, R.H., et al., “Nuclear delivery of p53 C-terminal peptides into cancer cells using scFv fragments of a monoclonal antibody that penetrates living cells,” Cancer Lett. 195(2):211-219, Elsevier, Netherlands (200… [cited by applicant]
Weisbart, R.H., et al., “Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53,” Int. J. Oncol. 25(4):1113-1118, Spandidos Publications, Greece (20… [cited by applicant]
Weisbart, R.H., et al., “An intracellular delivery vehicle for protein transduction of micro-dystrophin,” J. Drug. Target. 13(2):81-87, Informa, United Kingdom (2005). [cited by applicant]
Weisbart, R.H., et al., “A cell-penetrating bispecific antibody for therapeutic regulation of intracellular targets,” Mol. Cancer. Ther. 11(10):2169-2173, American Association for Cancer Research Inc., United States (20… [cited by applicant]
Zhan, X., et al., “Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats,” Stroke. 41(3):538-543, Lippincot Williams & Wilkins, United States (2010). [cited by applicant]
U.S. Appl. No. 18/054,101, Quijano, E. et al., filed Nov. 9, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 17/638,642, Quijano, E. et al., filed Feb. 25, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 17/823,496, Quijano, E. et al., filed Aug. 30, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 17/823,488, Quijano, E. et al., filed Aug. 30, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 17/823,494, Quijano, E. et al., filed Aug. 30, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 17/823,492, Quijano, E. et al., filed Aug. 30, 2022 (Not Published) (pending). [cited by applicant]
U.S. Appl. No. 18/054,080, Quijano, E. et al., filed Nov. 9, 2022 (Not Published) (pending). [cited by applicant]
Non-Final Office Action mailed Mar. 3, 2023 in U.S. Appl. No. 17/823,494, Quijano, E., et al., filed Aug. 30, 2022, 21 pages. [cited by applicant]
Zhumei , H., “9.3 Site-directed Mutagenesis of DNA in Vitro,” in [cited by applicant]
Non-Final Office Action mailed Aug. 29, 2024 in U.S. Appl. No. 17/272,151, Quijano, E., et al., § 371(c) Date: Feb. 26, 2021, 27 pages. [cited by applicant]
Bedell, V.M., et al., “In Vivo Genome Editing Using a High-efficiency TALEN System,” Nature 491(7422):114-118, Nature Publishing Group, United Kingdom (Nov. 2012). [cited by applicant]
Interview Summary mailed on Dec. 29, 2022, in U.S. Appl. No. 17/823,492, Quijano, E., et al., filed Aug. 30, 2022, 10 pages. [cited by applicant]
Liu, J., et al., “Cell-penetrating Peptide-mediated Delivery of TALEN Proteins via Bioconjugation for Genome Engineering,” PLoS One 9(1):e85755, Public Library of Science, United States (Jan. 2014). [cited by applicant]
McCaffrey, J., et al., “CRISPR-CAS9 D10A Nickase Target-specific Fluorescent Labeling of Double Strand DNA for Whole Genome Mapping and Structural Variation Analysis,” Nucleic Acids Research 44(2):e11, Oxford University… [cited by applicant]
Trevino, A.E., and Zhang, F., “Genome Editing Using Cas9 Nickases,” Methods in Enzymology 546:161-174, Academic Press, United States (2014). [cited by applicant]